In a newly published perspective article in Nature Nanotechnology, researchers highlighted nanoparticle-mediated targeting chimeras (NPTACs), a technology that overcomes tissue-penetration and off-target limitations of existing degradation tools. Arvinas, a leading biotech in targeted protein degradation, has already struck multi-billion-dollar partnerships with Pfizer—underscoring Pfizer’s strategic commitment to next-generation platforms. With the targeted protein degradation market forecast to exceed $10 billion by 2030, these collaborations position Pfizer to access modular, brain-penetrant technologies that could address oncology and neurodegenerative indications currently beyond the reach of small molecules or biologics.

Pfizer’s latest financial disclosures reveal a dividend yield above 6 percent, driven by depressed COVID vaccine revenues and recent patent expirations. Management has signaled that dividend growth remains a key priority while the company rebalances its portfolio. To diversify its pipeline, Pfizer entered a licensing agreement with YaoPharma for an emerging GLP-1 candidate, seeking to capture market share in metabolic therapies. Concurrently, the company has increased R&D investment in oncology, where several phase 2 assets are on track for mid-decade readouts. These moves aim to restore revenue momentum and support a sustainable payout ratio below 50 percent.

In a concurrent transaction to GSK’s acquisition of RAPT Therapeutics, Pfizer agreed to sell its 11.7 percent holding in ViiV Healthcare for $1.875 billion in cash. The divestiture allows Pfizer to redeploy capital toward high-growth franchises such as immuno-oncology and rare disease, while streamlining its equity investments. With Shionogi increasing its ViiV stake to 21.7 percent, Pfizer’s exit underscores a broader shift toward internal pipeline development and disciplined portfolio optimization.